Academic Department of Vascular Surgery, Charing Cross Hospital
London, W4 8RF, United Kingdom
NCT Number: NCT02114307
To investigate the efficacy of an electrical stimulation (using the REVITIVE IX device) in treating patients with venous insufficiency.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
London, W4 8RF, United Kingdom
This is a pilot randomised control trial to assess the efficacy of a neuromuscular electrical stimulation device to improve venous blood flow and patients' symptoms in patients with chronic venous insufficiency. The Revitive IX device is a neuromuscular electrical stimulation device that gives wide pulse pattern electrical stimulation via foot pads. A cycle of treatment consists of a 30 minute programme of 15 varying waveforms that last a minute each.
Twenty patients with venous insufficiency will be screened according the eligibility criteria. Patients will be randomised to either treatment or control (sham device) group. Patients are advised to use the device 30 minutes a day, everyday, for 6 weeks. Compliance will be monitored with a data logger and diary card.
Primary outcome measure:
a) improvement in venous haemodynamics.
Secondary outcome measures:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
neuromuscular electrical stimulation device
Time frame: 0 and 6 weeks
Femoral vein haemodynamics is measured using ultrasound scan - Time Averaged Mean Velocity
Time frame: 0 and 6 weeks
Lower limb oedema measured before and after using the device at 0 and 6 weeks using a perimeter.
Limb volume was measured using an optoelectronic limb volumeter. Patients using compression stockings were advised to remove stockings 2 h prior to their appointment. Measurements were taken with the patient seated and the affected leg in a horizontal position. Five readings were taken before and after device usage at Week 0 and Week 6
Time frame: 0 and 6 weeks
Change in clinical symptoms as assessed by the Venous Clinical Severity Score (VCSS) from 0 to 6 weeks, lower score means improvement. Maximum score on VCSS is 30. Minimum score is 0.
Imperial College London
Other
Acronym: RVI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00759434
Cardiovascular Diseases, Leg Ulcer
Hull, East Yorkshire, United Kingdom
View Trial DetailsNCT03850496
Cardiovascular Diseases, Leg Ulcer
View Trial DetailsNCT04006184
Cardiovascular Diseases, Varicose Veins
Bellevue, Washington, United States
View Trial DetailsNCT03283800
Cardiovascular Diseases, Chronic Venous Insufficiency
View Trial Details